RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models
Nadine Haase, … , Babbette LaMarca, Ralf Dechend
Nadine Haase, … , Babbette LaMarca, Ralf Dechend
Published April 27, 2020
Citation Information: J Clin Invest. 2020;130(6):2928-2942. https://doi.org/10.1172/JCI99417.
View: Text | PDF
Research Article Reproductive biology

RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models

Abstract

Authors

Nadine Haase, Donald J. Foster, Mark W. Cunningham, Julia Bercher, Tuyen Nguyen, Svetlana Shulga-Morskaya, Stuart Milstein, Sarfraz Shaikh, Jeff Rollins, Michaela Golic, Florian Herse, Kristin Kräker, Ivo Bendix, Meray Serdar, Hanna Napieczynska, Arnd Heuser, Alexandra Gellhaus, Kristin Thiele, Gerd Wallukat, Dominik N. Müller, Babbette LaMarca, Ralf Dechend

×

Figure 4

siRNA against hAgt improves fetal outcome.

Options: View larger image (or click on image) Download as PowerPoint
siRNA against hAgt improves fetal outcome. (A) Fetal weights were increa...
(A) Fetal weights were increased after application of hAgt-targeting siRNA (n = 102) versus luciferase-targeting siRNA (n = 80) (***P < 0.001; unpaired t test; mean ± SEM). (B) Frequency distribution curves for individual pups. A rightward shift of the curve for pups from the hAGT-targeting siRNA group (gray solid curve) compared with the luciferase-targeting siRNA group (black dashed curve) illustrates the improved fetal outcome. Vertical dashed line denotes the 10th percentile of luciferase-targeting siRNA–treated PE fetal weights. (C) Fetal growth restriction is shown as the ratio between fetal brain and liver weights. Application of hAgt-targeting siRNA (n = 49) decreased the fetal brain/liver weight ratio compared with luciferase-targeting siRNA (n = 44) (***P < 0.001; Mann-Whitney test; mean ± SEM).